Phase I/II study of RVT-1801 in patients with sickle cell disease
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2018
Price : $35 *
At a glance
- Drugs RVT 1801 (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Sponsors Aruvant Sciences
- 07 Dec 2018 New trial record
- 04 Dec 2018 According to an Aruvant Sciences media release, Punam Malik, MD (physician-scientist at the Cincinnati Children's Cancer and Blood Diseases Institute and director of its Comprehensive Sickle Cell Center) is the principal investigator of this trial.
- 03 Dec 2018 Results presented in the Aruvant Sciences media release.